222 related articles for article (PubMed ID: 29917295)
1. A452, an HDAC6-selective inhibitor, synergistically enhances the anticancer activity of chemotherapeutic agents in colorectal cancer cells.
Won HR; Ryu HW; Shin DH; Yeon SK; Lee DH; Kwon SH
Mol Carcinog; 2018 Oct; 57(10):1383-1395. PubMed ID: 29917295
[TBL] [Abstract][Full Text] [Related]
2. A potent hydroxamic acid-based, small-molecule inhibitor A452 preferentially inhibits HDAC6 activity and induces cytotoxicity toward cancer cells irrespective of p53 status.
Ryu HW; Shin DH; Lee DH; Won HR; Kwon SH
Carcinogenesis; 2018 Jan; 39(1):72-83. PubMed ID: 29106445
[TBL] [Abstract][Full Text] [Related]
3. A452, HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in IMiDs-resistant multiple myeloma.
Kim GW; Yoo J; Won HR; Yeon SK; Lee SW; Lee DH; Jeon YH; Kwon SH
Leuk Res; 2020 Aug; 95():106398. PubMed ID: 32512378
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents.
Namdar M; Perez G; Ngo L; Marks PA
Proc Natl Acad Sci U S A; 2010 Nov; 107(46):20003-8. PubMed ID: 21037108
[TBL] [Abstract][Full Text] [Related]
5. HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma.
Lee SW; Yeon SK; Kim GW; Lee DH; Jeon YH; Yoo J; Kim SY; Kwon SH
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572814
[TBL] [Abstract][Full Text] [Related]
6. The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma.
Lee DH; Kim GW; Kwon SH
Mol Carcinog; 2019 Jun; 58(6):944-956. PubMed ID: 30693983
[TBL] [Abstract][Full Text] [Related]
7. HDAC6‑selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in multiple myeloma.
Won HR; Lee DH; Yeon SK; Ryu HW; Kim GW; Kwon SH
Int J Oncol; 2019 Aug; 55(2):499-512. PubMed ID: 31268156
[TBL] [Abstract][Full Text] [Related]
8. The HDAC6 inhibitor ACY‑1215 enhances the anticancer activity of oxaliplatin in colorectal cancer cells.
Lee DH; Won HR; Ryu HW; Han JM; Kwon SH
Int J Oncol; 2018 Aug; 53(2):844-854. PubMed ID: 29749542
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide-resistant Glioblastoma Depends on HDAC6 Activity Through Regulation of DNA Mismatch Repair.
Kim GW; Lee DH; Yeon SK; Jeon YH; Yoo J; Lee SW; Kwon SH
Anticancer Res; 2019 Dec; 39(12):6731-6741. PubMed ID: 31810938
[TBL] [Abstract][Full Text] [Related]
10. Aceroside VIII is a new natural selective HDAC6 inhibitor that synergistically enhances the anticancer activity of HDAC inhibitor in HT29 cells.
Ryu HW; Lee DH; Shin DH; Kim SH; Kwon SH
Planta Med; 2015 Feb; 81(3):222-7. PubMed ID: 25590368
[TBL] [Abstract][Full Text] [Related]
11. Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine.
Cosenza M; Civallero M; Marcheselli L; Sacchi S; Pozzi S
Apoptosis; 2017 Jun; 22(6):827-840. PubMed ID: 28315173
[TBL] [Abstract][Full Text] [Related]
12. The histone deacetylase inhibitor trichostatin A induces cell cycle arrest and apoptosis in colorectal cancer cells via p53-dependent and -independent pathways.
Meng J; Zhang HH; Zhou CX; Li C; Zhang F; Mei QB
Oncol Rep; 2012 Jul; 28(1):384-8. PubMed ID: 22552631
[TBL] [Abstract][Full Text] [Related]
13. 4-Hydroxybenzoic acid (4-HBA) enhances the sensitivity of human breast cancer cells to adriamycin as a specific HDAC6 inhibitor by promoting HIPK2/p53 pathway.
Wang XN; Wang KY; Zhang XS; Yang C; Li XY
Biochem Biophys Res Commun; 2018 Oct; 504(4):812-819. PubMed ID: 30217455
[TBL] [Abstract][Full Text] [Related]
14. Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA.
Heinicke U; Fulda S
Cancer Lett; 2014 Aug; 351(1):50-8. PubMed ID: 24814395
[TBL] [Abstract][Full Text] [Related]
15. Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
Alzoubi S; Brody L; Rahman S; Mahul-Mellier AL; Mercado N; Ito K; El-Bahrawy M; Silver A; Boobis A; Bell JD; Hajji N
Oncotarget; 2016 Jul; 7(28):44505-44521. PubMed ID: 27283986
[TBL] [Abstract][Full Text] [Related]
16. HDAC6-selective inhibitors enhance anticancer effects of paclitaxel in ovarian cancer cells.
Yoo J; Jeon YH; Lee DH; Kim GW; Lee SW; Kim SY; Park J; Kwon SH
Oncol Lett; 2021 Mar; 21(3):201. PubMed ID: 33574940
[TBL] [Abstract][Full Text] [Related]
17. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X
J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933
[TBL] [Abstract][Full Text] [Related]
18. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model.
Maharaj K; Powers JJ; Mediavilla-Varela M; Achille A; Gamal W; Quayle S; Jones SS; Sahakian E; Pinilla-Ibarz J
Front Immunol; 2020; 11():590072. PubMed ID: 33329575
[TBL] [Abstract][Full Text] [Related]
19. The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines.
Kolbinger FR; Koeneke E; Ridinger J; Heimburg T; Müller M; Bayer T; Sippl W; Jung M; Gunkel N; Miller AK; Westermann F; Witt O; Oehme I
Arch Toxicol; 2018 Aug; 92(8):2649-2664. PubMed ID: 29947893
[TBL] [Abstract][Full Text] [Related]
20. Quinazolin-2,4-dione-Based Hydroxamic Acids as Selective Histone Deacetylase-6 Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Yu CW; Hung PY; Yang HT; Ho YH; Lai HY; Cheng YS; Chern JW
J Med Chem; 2019 Jan; 62(2):857-874. PubMed ID: 30525585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]